The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

Boehringer Ingelheim received approval from the Food and Drug Administration for Hernexeos as a treatment for lung cancer. The newly approved indication was granted under accelerated approval based on ...

NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...